PDCD1 and esophageal squamous cell carcinoma: In recent years, piles of small-sample-size studies have investigated the preliminary efficacy of PD-1 inhibitors plus chemotherapy in locally advanced ESCC, with pCR ranging from 21.7 to 50.0% and MPR from 44.4 to 72.0% [17, 19, 29–32].